Comparison of Anatomical and Functional Outcomes of Intravitreal Dexamethasone Implant between Phakic and Pseudophakic Eyes with Diabetic Macular Edema
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare the effectiveness of dexamethasone (DEX) intravitreal implants for the treatment of diabetic macularedema between phakic and pseudophakic eyes after a follow-up. Methods: A total of 79 eyes in 79 patients with diabetic macular edema who were insufficiently responsive to the previousanti-vascular endothelial growth factor treatment and applied intravitreal DEX implant were included in this retrospectivestudy. The patients were divided into two groups according to their type of lenses: pseudophakic (group 1) and phakic (group 2). Best-corrected visual acuity, intraocular pressure (IOP), retinal nerve fiber layer thickness, and central macular thicknesschanges in the two groups were compared. Results: Group 1 comprised 42 eyes in 42 patients with a mean age of 64.02 ± 3.79 years, while group 2 comprised 37 eyes in37 patients with a mean age of 64.19 ± 5.08 years. In both groups, best-corrected visual acuity improved significantly with asignificant decrease in central macular thickness (p < 0.001). In both lens types, the IOP values decreased significantly on thefirst day but subsequently increased significantly compared to baseline from one week to six months. Increases in IOP valueswere significantly higher in group 1 at the first week, 1st month, and 6th month compared with group 2. During follow-up,the inferior quadrant retinal nerve fiber layer showed a significant decrease in both groups. Conclusions: In both phakic and pseudophakic eyes, intravitreal DEX implantation is an effective treatment method withlow-risk complications. In our study, the pseudophakic group experienced a significantly earlier increase in IOP and at higherlevels than did the phakic group. In light of these data, we suggest that in patients with pseudophakic eyes, follow-ups for IOPshould be stricter and started earlier after intravitreal DEX treatment.
Abstract
Purpose: To compare the effectiveness of dexamethasone (DEX) intravitreal implants for the treatment of diabetic macularedema between phakic and pseudophakic eyes after a follow-up. Methods: A total of 79 eyes in 79 patients with diabetic macular edema who were insufficiently responsive to the previousanti-vascular endothelial growth factor treatment and applied intravitreal DEX implant were included in this retrospectivestudy. The patients were divided into two groups according to their type of lenses: pseudophakic (group 1) and phakic (group 2). Best-corrected visual acuity, intraocular pressure (IOP), retinal nerve fiber layer thickness, and central macular thicknesschanges in the two groups were compared. Results: Group 1 comprised 42 eyes in 42 patients with a mean age of 64.02 ± 3.79 years, while group 2 comprised 37 eyes in37 patients with a mean age of 64.19 ± 5.08 years. In both groups, best-corrected visual acuity improved significantly with asignificant decrease in central macular thickness (p < 0.001). In both lens types, the IOP values decreased significantly on thefirst day but subsequently increased significantly compared to baseline from one week to six months. Increases in IOP valueswere significantly higher in group 1 at the first week, 1st month, and 6th month compared with group 2. During follow-up,the inferior quadrant retinal nerve fiber layer showed a significant decrease in both groups. Conclusions: In both phakic and pseudophakic eyes, intravitreal DEX implantation is an effective treatment method withlow-risk complications. In our study, the pseudophakic group experienced a significantly earlier increase in IOP and at higherlevels than did the phakic group. In light of these data, we suggest that in patients with pseudophakic eyes, follow-ups for IOPshould be stricter and started earlier after intravitreal DEX treatment.
참고문헌 (35)
- Williams R, "Epidemiology of diabetic retinopathy and macular oedema: a systematic review", Eye(Lond), 18, pp.963~983 (2004)
- Yau JW, "Global prevalence and major risk factors of diabetic retinopathy", Diabetes Care, 35, pp.556~564 (2012)
- Lattanzio R, "Intravitreal steroids in diabetic macular edema", Dev Ophthalmol, 60, pp.78~90 (2017)
- Qian TW, "Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema : a systematic review and Meta-analysis", Int J Ophthalmol, 10, pp.1134~1143 (2017)
- Wu Y, "Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema : a Bayesian network meta-analysis", Biomed Pharmacother, 97, pp.293~299 (2018)
- Chang-Lin JE, "Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant", Invest Ophthalmol Vis Sci, 52, pp.80~86 (2011)
- Meyer LM, "Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up", J Ocul Pharmacol Ther, 29, pp.560~565 (2013)
- Krohne TU, "Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors", Retina, 35, pp.69~74 (2015)
- Boyer DS, "Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema", Ophthalmology, 121, pp.1904~1914 (2014)
- Guigou S, "Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema", Ophthalmologica, 233, pp.169~175 (2015)
- Pacella E, "Preliminary results of an intravitreal dexamethasone implant(Ozurdex)in patients with persistent diabetic macular edema", Clin Ophthalmol, 7, pp.1423~1428 (2013)
- Diabetic Retinopathy Clinical Research Network, "Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment : three-year randomized trial results", Ophthalmology, 119, pp.2312~2318 (2012)
- Blumenkranz MS, "Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema", Retina, 30, pp.1090~1094 (2010)
- Moon BG, "Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea", J Ophthalmol, 2016, pp.9810270~ (2016)
- Erkan Unsal, "Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema", Korean Journal of Ophthalmology, 31(2), pp.115~122 (2017), 대한안과학회
- Khan Z, "Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy : meta-analysis and clinical implications", Ophthalmic Surg Lasers Imaging Retina, 48, pp.160~166 (2017)
- Totan Y, "Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment", Curr Eye Res, 41, pp.107~113 (2016)
- Clark AF, "Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue", Cell Motil Cytoskeleton, 60, pp.83~95 (2005)
- Zhou L, "Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma", Int J Mol Med, 1, pp.339~346 (1998)
- Johnson DH, "The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture", Invest Ophthalmol Vis Sci, 31, pp.2568~2571 (1990)
- Chin EK, "Ccular hypertension after intravitreal dexamethasone(Ozurdex)sustained-release implant", Retina, 37, pp.1345~1351 (2017)
- Maturi RK, "Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study", Retina, 36, pp.1143~1152 (2016)
- Capone A Jr, "Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion(Shasta study)", Retina, 34, pp.342~351 (2014)
- Quigley HA, "Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats", Invest Ophthalmol Vis Sci, 41, pp.3460~3466 (2000)
- Boland MV, "Preventive Services Task Force", Ann Intern Med, 158, pp.271~279 (2013)
- Bucolo C, "Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema : A systematic review of real-world studies", J Pharmacol Sci, 138, pp.219~232 (2018)
- Garcia-Martin E, "Neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy", J Ophthalmol, 2019, pp.1825819~ (2019)
- Pieroth L, "Evaluation of focal defects of the nerve fiber layer using optical coherence tomography", Ophthalmology, 106, pp.570~579 (1999)
- Schuman JS, "Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography", Ophthalmology, 103, pp.1889~1898 (1996)
- Quigley HA, "Quantitative studies of retinal nerve fiber layer defects", Arch Ophthalmol, 100, pp.807~814 (1982)
- Ayar O, "The effect of dexamethasone intravitreal implant on retinal nerve fiber layer in patients diagnosed with branch retinal vein occlusion", Curr Eye Res, 42, pp.1287~1292 (2017)
- Bulut MN, "Evaluation of peripapillary nerve fiber layer after dexamethasone implantation(Ozurdex)in branch retinal vein occlusions", J Ophthalmol, 2016, pp.2050796~ (2016)
- Khurana RN, "Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies", Ophthalmology, 121, pp.67~71 (2014)
- Esen E, "Two cases of acute endophthalmitis after intravitreal dexamethasone implant injection", Retin Cases Brief Rep, 10, pp.154~156 (2016)
- Kucukevcilioglu M, "Acute retinal necrosis following intravitreal dexamethasone(Ozurdex)implant", Arq Bras Oftalmol, 78, pp.118~119 (2015)